Novel biomarkers for diabetic nephropathy
Research type
Research Study
Full title
Novel biomarkers for diabetic nephropathy detection, stratification and progression
IRAS ID
244442
Contact name
Diego Cobice
Contact email
Sponsor organisation
Ulster University
Duration of Study in the UK
4 years, months, 0 days
Research summary
Diabetes is a disease that affects around 400 million people worldwide, a number that is expected to rise to 592 million by 2035. Diabetic nephropathy (DN) is a complication affecting the kidneys arising from diabetes. It is currently the leading cause of end-stage kidney disease which means patients require the use of dialysis and possibly renal transplantation.
At present, DN is diagnosed by measuring a specific protein in the urine. This method, however, is not always reliable and kidney damage has already occurred by the time a diagnosis is made.
This study hopes to identify a more effective diagnosis method for diabetic nephropathy by analysing blood and urine, and collecting data from 1) individuals without diabetes (n=20-50), 2) individuals with diabetes (n=20-50) and 3) diabetic patients with DN (n=20-50). If identified, a diagnostic test can be developed using this method which will allow for early diagnosis and, therefore, early treatment of DN. This may prevent further kidney damage and other complications.REC name
London - Chelsea Research Ethics Committee
REC reference
18/LO/0785
Date of REC Opinion
20 May 2018
REC opinion
Further Information Favourable Opinion